Literature DB >> 17663957

[Emotional disorders and psychological needs of patients in an Intensive Care Unit].

P Gómez-Carretero1, V Monsalve, J F Soriano, J de Andrés.   

Abstract

From the time when a disease whose treatment is going to require hospitalization for a surgical intervention is diagnosed, both the patient and his/her family members or primary caretakers are involved in a process that may involve the experience of several emotional alterations. This work focuses on the description of the different psychological problems and needs manifested by the patients who require, as part of the treatment process and recovery control, admission to an Intensive Care Unit (ICU). During the patient's stay in the ICU, the emotional alterations mentioned most frequently by them are anxiety, stress, depression or the so-called intensive care syndrome, during which factors such as excessive noise that may make sleeping and rest difficult, pain, the methods used for ventilation that prevent the patients from communicating adequately, etc. Furthermore, the patients generally develop a feeling of loss of self-control, the main needs described being the sensation of safety and "knowing what is happening". The experiences lived may continue to produce emotional alterations even months after hospital discharge, with the development of a Posttraumatic Stress Disorder. This justifies a follow-up in order to detect them and treat them adequately. It seems to be appropriate for the treatment of these patients to be multidisciplinary, attending to both the physical needs related with the disease as well as the psychological ones.

Entities:  

Mesh:

Year:  2007        PMID: 17663957     DOI: 10.1016/s0210-5691(07)74830-1

Source DB:  PubMed          Journal:  Med Intensiva        ISSN: 0210-5691            Impact factor:   2.491


  1 in total

Review 1.  Post-traumatic stress disorder in medical settings: focus on the critically ill.

Authors:  O Joseph Bienvenu; Karin J Neufeld
Journal:  Curr Psychiatry Rep       Date:  2011-02       Impact factor: 5.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.